{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:00:47Z","timestamp":1794524447406,"version":"4.9.1"},"reference-count":260,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["APP0601"],"award-info":[{"award-number":["APP0601"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["APP0602"],"award-info":[{"award-number":["APP0602"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["APD0045"],"award-info":[{"award-number":["APD0045"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["Recovery and Resilience Plan for Slovakia project No. 09I01-03-V04-00073"],"award-info":[{"award-number":["Recovery and Resilience Plan for Slovakia project No. 09I01-03-V04-00073"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-20-0143"],"award-info":[{"award-number":["APVV-20-0143"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-21-0197"],"award-info":[{"award-number":["APVV-21-0197"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010783","name":"Slovensk\u00e1 Akad\u00e9mia Vied","doi-asserted-by":"publisher","award":["TRANSCAN2023-1858-117"],"award-info":[{"award-number":["TRANSCAN2023-1858-117"]}],"id":[{"id":"10.13039\/100010783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-026-02081-5","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:24:45Z","timestamp":1771687485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Epigenetic modulation to overcome immune suppression in pancreatic cancer"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5412-1982","authenticated-orcid":false,"given":"Laura","family":"Drndakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8082-9029","authenticated-orcid":false,"given":"Lucia","family":"Juhasikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0533-4745","authenticated-orcid":false,"given":"Ivana","family":"Hlavenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-9126","authenticated-orcid":false,"given":"Verona","family":"Buocikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Durdiakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Buc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4906-5652","authenticated-orcid":false,"given":"Bozena","family":"Smolkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"1","key":"2081_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-020-00184-0","volume":"9","author":"HL Gao","year":"2020","unstructured":"Gao HL, Wang WQ, Yu XJ, Liu L. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Exp Hematol Oncol. 2020;9(1):28. https:\/\/doi.org\/10.1186\/s40164-020-00184-0.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"2081_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.biocel.2004.07.010","volume":"37","author":"A Grapin-Botton","year":"2005","unstructured":"Grapin-Botton A. Ductal cells of the pancreas. Int J Biochem Cell Biol. 2005;37(3):504\u201310.","journal-title":"Int J Biochem Cell Biol"},{"key":"2081_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/apc.2019.06.03","volume":"2","author":"Y Xu","year":"2019","unstructured":"Xu Y, Liu J, Nipper M, Wang P. Ductal vs. acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma. Ann Pancreat Cancer. 2019;2:11\u201311.","journal-title":"Ann Pancreat Cancer"},{"issue":"1","key":"2081_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41698-024-00571-4","volume":"8","author":"M Abdelrahim","year":"2024","unstructured":"Abdelrahim M, Esmail A, Kasi A, Esnaola NF, Xiu J, Baca Y, et al. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. Npj Precis Oncol. 2024;8(1):85.","journal-title":"Npj Precis Oncol"},{"issue":"3","key":"2081_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10689-024-00372-5","volume":"23","author":"MF Jacobs","year":"2024","unstructured":"Jacobs MF, Stoffel EM. Genetic and other risk factors for pancreatic ductal adenocarcinoma (PDAC). Fam Cancer. 2024;23(3):221\u201332. https:\/\/doi.org\/10.1007\/s10689-024-00372-5.","journal-title":"Fam Cancer"},{"issue":"6","key":"2081_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/jso.26994","volume":"126","author":"JL McGarry","year":"2022","unstructured":"McGarry JL, Creavin B, Kelly ME, Gallagher TK. Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and\/or BRCA2 mutation: a systematic review and meta-analysis. J Surg Oncol. 2022;126(6):1028\u201337. https:\/\/doi.org\/10.1002\/jso.26994.","journal-title":"J Surg Oncol"},{"issue":"32","key":"2081_CR7","doi-asserted-by":"publisher","first-page":"11182","DOI":"10.3748\/wjg.v20.i32.11182","volume":"20","author":"AE Becker","year":"2014","unstructured":"Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014;20(32):11182\u201398.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2081_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32(2):185\u2013e20313.","journal-title":"Cancer Cell"},{"key":"2081_CR9","doi-asserted-by":"publisher","first-page":"e2300092","DOI":"10.1200\/PO.23.00092","volume":"7","author":"JCF Quintanilha","year":"2023","unstructured":"Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, et al. Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis Oncol. 2023;7:e2300092.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"2081_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, Xu D, Liao MM, Sun Y, Bao WD, Yao F, et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024;8(1):199.","journal-title":"NPJ Precis Oncol"},{"key":"2081_CR11","doi-asserted-by":"publisher","first-page":"217699","DOI":"10.1016\/j.canlet.2025.217699","volume":"622","author":"K Brautigam","year":"2025","unstructured":"Brautigam K, Skok K, Szymonski K, Rift CV, Karamitopoulou E. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited-exploring the space. Cancer Lett. 2025;622:217699.","journal-title":"Cancer Lett"},{"issue":"1","key":"2081_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bbcan.2012.04.002","volume":"1826","author":"G Luo","year":"2012","unstructured":"Luo G, Long J, Zhang B, Liu C, Xu J, Ni Q, et al. Stroma and pancreatic ductal adenocarcinoma: an interaction loop. Biochim Biophys Acta - Rev Cancer. 2012;1826(1):170\u20138.","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"issue":"17","key":"2081_CR13","doi-asserted-by":"publisher","first-page":"18020","DOI":"10.1002\/cam4.6407","volume":"12","author":"S Byeon","year":"2023","unstructured":"Byeon S, du Toit-Thompson T, Gillson J, Gill AJ, Samra JS, Mittal A, et al. Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: an emerging role of single\u2010cell analysis. Cancer Med. 2023;12(17):18020\u201331.","journal-title":"Cancer Med"},{"issue":"10","key":"2081_CR14","doi-asserted-by":"publisher","first-page":"e13441","DOI":"10.1371\/journal.pone.0013441","volume":"5","author":"V Tjomsland","year":"2010","unstructured":"Tjomsland V, Spangeus A, Sandstrom P, Borch K, Messmer D, Larsson M. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS ONE. 2010;5(10):e13441.","journal-title":"PLoS ONE"},{"key":"2081_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2019.00496","volume":"10","author":"SA Lim","year":"2019","unstructured":"Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, et al. Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients. Front Immunol. 2019;10:496.","journal-title":"Front Immunol"},{"issue":"1","key":"2081_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s40425-019-0734-6","volume":"7","author":"R Trovato","year":"2019","unstructured":"Trovato R, Fiore A, Sartori S, Can\u00e8 S, Giugno R, Cascione L, et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer. 2019;7(1):255.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2081_CR17","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.3390\/cancers15092614","volume":"15","author":"A Brichkina","year":"2023","unstructured":"Brichkina A, Polo P, Sharma SD, Visestamkul N, Lauth M. A quick guide to CAF subtypes in pancreatic cancer. Cancers (Basel). 2023;15(9):2614.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2081_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1158\/2326-6066.CIR-22-0398","volume":"11","author":"V Lutz","year":"2023","unstructured":"Lutz V, Hellmund VM, Picard FSR, Raifer H, Ruckenbrod T, Klein M, et al. IL18 receptor signaling regulates Tumor-Reactive CD8\u2009+\u2009T-cell exhaustion via activation of the IL2\/STAT5\/mTOR pathway in a pancreatic cancer model. Cancer Immunol Res. 2023;11(4):421\u201334.","journal-title":"Cancer Immunol Res"},{"key":"2081_CR19","doi-asserted-by":"crossref","unstructured":"Liu P, Jacques J, Hwang CI. Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma. Vol. 8, Epigenomes. 2024.","DOI":"10.20944\/preprints202409.0155.v1"},{"issue":"9","key":"2081_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2081_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-022-05351-1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang T, Ren Y, Yang P, Wang J, Zhou H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13(10):897.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2081_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"46","key":"2081_CR23","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.3748\/wjg.v27.i46.7956","volume":"27","author":"MR Goulart","year":"2021","unstructured":"Goulart MR, Stasinos K, Fincham REA, Delvecchio FR, Kocher HM. T cells in pancreatic cancer stroma. World J Gastroenterol. 2021;27(46):7956\u201368.","journal-title":"World J Gastroenterol"},{"key":"2081_CR24","doi-asserted-by":"crossref","unstructured":"Dzobo K, Senthebane DA, Dandara C. The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers (Basel). 2023;15(2).","DOI":"10.3390\/cancers15020376"},{"key":"2081_CR25","doi-asserted-by":"crossref","unstructured":"Abou Khouzam R, Lehn JM, Mayr H, Clavien PA, Wallace MB, Ducreux M et al. Hypoxia, a targetable culprit to counter pancreatic cancer resistance to therapy. Cancers (Basel). 2023;15(4).","DOI":"10.3390\/cancers15041235"},{"issue":"6","key":"2081_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrc3726","volume":"14","author":"DM Gilkes","year":"2014","unstructured":"Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2081_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29.","journal-title":"Mol Cancer"},{"issue":"2","key":"2081_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/0008-5472.CAN-18-1334","volume":"79","author":"KY Elahi-Gedwillo","year":"2019","unstructured":"Elahi-Gedwillo KY, Carlson M, Zettervall J, Provenzano PP. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 2019;79(2):372\u201386.","journal-title":"Cancer Res"},{"issue":"3","key":"2081_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418\u201329.","journal-title":"Cancer Cell"},{"issue":"8","key":"2081_CR30","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/2159-8290.CD-15-0947","volume":"6","author":"M Waghray","year":"2016","unstructured":"Waghray M, Yalamanchili M, Dziubinski M, Zeinali M, Erkkinen M, Yang H, et al. GM-CSF mediates mesenchymal\u2013epithelial cross-talk in pancreatic cancer. Cancer Discov. 2016;6(8):886\u201399.","journal-title":"Cancer Discov"},{"issue":"3","key":"2081_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neo.2016.01.005","volume":"18","author":"E Mathew","year":"2016","unstructured":"Mathew E, Brannon AL, Del Vecchio A, Garcia PE, Penny MK, Kane KT, et al. Mesenchymal stem cells promote pancreatic tumor growth by inducing alternative polarization of macrophages. Neoplasia. 2016;18(3):142\u201351.","journal-title":"Neoplasia"},{"issue":"19","key":"2081_CR32","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184(19):5031\u2013e505226.","journal-title":"Cell"},{"issue":"24","key":"2081_CR33","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1158\/0008-5472.CAN-16-0300","volume":"76","author":"ME Gilles","year":"2016","unstructured":"Gilles ME, Maione F, Cossutta M, Carpentier G, Caruana L, Di Maria S, et al. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 2016;76(24):7181\u201393.","journal-title":"Cancer Res"},{"issue":"1","key":"2081_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-018-0815-z","volume":"17","author":"Y Fu","year":"2018","unstructured":"Fu Y, Liu S, Zeng S, Shen H. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma. Mol Cancer. 2018;17(1):62. https:\/\/doi.org\/10.1186\/s12943-018-0815-z.","journal-title":"Mol Cancer"},{"key":"2081_CR35","doi-asserted-by":"publisher","unstructured":"Du Y, Zhao Y, Li J, Wang J, You S, Zhang Y, et al. PLXDC1\u2009+\u2009Tumor-Associated pancreatic stellate cells promote desmoplastic and immunosuppressive niche in pancreatic ductal adenocarcinoma. Adv Sci. 2025;12(18). https:\/\/doi.org\/10.1002\/advs.202415756.","DOI":"10.1002\/advs.202415756"},{"issue":"1","key":"2081_CR36","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1038\/s41467-023-40314-w","volume":"14","author":"M Xue","year":"2023","unstructured":"Xue M, Zhu Y, Jiang Y, Han L, Shi M, Su R, et al. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Nat Commun. 2023;14(1):4600.","journal-title":"Nat Commun"},{"issue":"4","key":"2081_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41416-023-02539-w","volume":"130","author":"B Zhang","year":"2024","unstructured":"Zhang B, Guo X, Huang L, Zhang Y, Li Z, Su D, et al. Tumour-associated macrophages and Schwann cells promote perineural invasion via paracrine loop in pancreatic ductal adenocarcinoma. Br J Cancer. 2024;130(4):542\u201354.","journal-title":"Br J Cancer"},{"issue":"2","key":"2081_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/13543784.2019.1557145","volume":"28","author":"S Chandana","year":"2019","unstructured":"Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs. 2019;28(2):161\u201377.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2081_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","volume":"43","author":"W Luo","year":"2024","unstructured":"Luo W, Wen T, Qu X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J Exp Clin Cancer Res. 2024;43(1):8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"2081_CR40","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jamasurg.2025.1999","volume":"160","author":"H Kim","year":"2025","unstructured":"Kim H, Choi JH, Lim Y, Yoon SJ, Jang KT, Ock CY, et al. Artificial Intelligence-Powered Spatial analysis of immune phenotypes in resected pancreatic cancer. JAMA Surg. 2025;160(8):884\u201392.","journal-title":"JAMA Surg"},{"issue":"10","key":"2081_CR41","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.011.","journal-title":"Immunity"},{"issue":"1","key":"2081_CR42","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14(1):5110.","journal-title":"Nat Commun"},{"key":"2081_CR43","doi-asserted-by":"crossref","unstructured":"Muller M, Haghnejad V, Schaefer M, Gauchotte G, Caron B, Peyrin-Biroulet L et al. The immune landscape of human pancreatic ductal carcinoma: key Players, clinical Implications, and challenges. Cancers (Basel). 2022;14(4).","DOI":"10.3390\/cancers14040995"},{"key":"2081_CR44","doi-asserted-by":"publisher","first-page":"1084887","DOI":"10.3389\/fimmu.2023.1084887","volume":"14","author":"A Tiwari","year":"2023","unstructured":"Tiwari A, Oravecz T, Dillon LA, Italiano A, Audoly L, Fridman WH, et al. Towards a consensus definition of immune exclusion in cancer. Front Immunol. 2023;14:1084887.","journal-title":"Front Immunol"},{"issue":"1","key":"2081_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng B, Wu J, Shen B, Jiang F, Feng J. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell Int. 2022;22(1):166.","journal-title":"Cancer Cell Int"},{"key":"2081_CR46","doi-asserted-by":"crossref","unstructured":"Kim I, Choi S, Yoo S, Lee M, Kim IS. Cancer-Associated fibroblasts in the hypoxic tumor microenvironment. Cancers (Basel). 2022;14(14).","DOI":"10.3390\/cancers14143321"},{"issue":"1","key":"2081_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17(1):40.","journal-title":"J Hematol Oncol"},{"key":"2081_CR48","doi-asserted-by":"publisher","first-page":"702726","DOI":"10.3389\/fimmu.2021.702726","volume":"12","author":"EN Scott","year":"2021","unstructured":"Scott EN, Gocher AM, Workman CJ, Vignali DAA, Regulatory T. Cells: barriers of immune infiltration into the tumor microenvironment. Front Immunol. 2021;12:702726.","journal-title":"Front Immunol"},{"issue":"7","key":"2081_CR49","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523\u201332.","journal-title":"Nat Rev Immunol"},{"issue":"Pt 2","key":"2081_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2022.08.009","volume":"86","author":"X Li","year":"2022","unstructured":"Li X, Gulati M, Larson AC, Solheim JC, Jain M, Kumar S, et al. Immune checkpoint Blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol. 2022;86(Pt 2):14\u201327.","journal-title":"Semin Cancer Biol"},{"key":"2081_CR51","doi-asserted-by":"publisher","first-page":"103958","DOI":"10.1016\/j.ebiom.2022.103958","volume":"78","author":"J Yang","year":"2022","unstructured":"Yang J, Zhang Q, Wang J, Lou Y, Hong Z, Wei S, et al. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. EBioMedicine. 2022;78:103958.","journal-title":"EBioMedicine"},{"key":"2081_CR52","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.3389\/fimmu.2019.03070","volume":"10","author":"C Siret","year":"2019","unstructured":"Siret C, Collignon A, Silvy F, Robert S, Cheyrol T, Andre P, et al. Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. Front Immunol. 2019;10:3070.","journal-title":"Front Immunol"},{"issue":"5","key":"2081_CR53","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2006-11-010389","volume":"108","author":"M Munder","year":"2006","unstructured":"Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, et al. Suppression of T-cell functions by human granulocyte arginase. Blood. 2006;108(5):1627\u201334.","journal-title":"Blood"},{"issue":"7","key":"2081_CR54","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8\u2009+\u2009T cell tolerance in cancer. Nat Med. 2007;13(7):828\u201335.","journal-title":"Nat Med"},{"issue":"6","key":"2081_CR55","doi-asserted-by":"publisher","first-page":"e13107","DOI":"10.1111\/sji.13107","volume":"94","author":"V Sharma","year":"2021","unstructured":"Sharma V, Sachdeva N, Gupta V, Nada R, Jacob J, Sahni D, et al. IL-6 is associated with expansion of myeloid-derived suppressor cells and enhanced immunosuppression in pancreatic adenocarcinoma patients. Scand J Immunol. 2021;94(6):e13107.","journal-title":"Scand J Immunol"},{"issue":"3","key":"2081_CR56","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: How does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"2081_CR57","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303\u201311.","journal-title":"Clin Genet"},{"issue":"11","key":"2081_CR58","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s12272-017-0973-3","volume":"40","author":"QA Abdul","year":"2017","unstructured":"Abdul QA, Yu BP, Chung HY, Jung HA, Choi JS. Epigenetic modifications of gene expression by lifestyle and environment. Arch Pharm Res. 2017;40(11):1219\u201337.","journal-title":"Arch Pharm Res"},{"key":"2081_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.semcancer.2025.01.003","volume":"109","author":"J Tost","year":"2025","unstructured":"Tost J, Ak-Aksoy S, Campa D, Corradi C, Farinella R, Ibanez-Costa A, et al. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Semin Cancer Biol. 2025;109:101\u201324.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2081_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28.","journal-title":"Cell Death Discov"},{"key":"2081_CR61","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.gene.2004.02.043","volume":"333","author":"K Jabbari","year":"2004","unstructured":"Jabbari K, Bernardi G. Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene. 2004;333:143\u20139.","journal-title":"Gene"},{"issue":"1","key":"2081_CR62","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41467-018-04383-6","volume":"9","author":"G Lomberk","year":"2018","unstructured":"Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 2018;9(1):1978.","journal-title":"Nat Commun"},{"issue":"10","key":"2081_CR63","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168\u201378.","journal-title":"Nat Genet"},{"issue":"21","key":"2081_CR64","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1158\/0008-5472.CAN-20-0672","volume":"80","author":"S Patil","year":"2020","unstructured":"Patil S, Steuber B, Kopp W, Kari V, Urbach L, Wang X, et al. EZH2 regulates pancreatic cancer subtype identity and tumor progression via transcriptional repression of GATA6. Cancer Res. 2020;80(21):4620\u201332.","journal-title":"Cancer Res"},{"key":"2081_CR65","doi-asserted-by":"crossref","unstructured":"Roalso MTT, Hald OH, Alexeeva M, Soreide K. Emerging role of epigenetic alterations as biomarkers and novel targets for treatments in pancreatic ductal adenocarcinoma. Cancers (Basel). 2022;14(3).","DOI":"10.3390\/cancers14030546"},{"key":"2081_CR66","doi-asserted-by":"publisher","unstructured":"Liu S, Kang S, Lin N, Zhang W, Wang S, Ren Y, et al. The TET3\/GATA6 axis drives lipid metabolism and therapeutic vulnerabilities in pancreatic ductal adenocarcinoma. Adv Sci. 2025;12(37). https:\/\/doi.org\/10.1002\/advs.202501774.","DOI":"10.1002\/advs.202501774"},{"key":"2081_CR67","doi-asserted-by":"crossref","unstructured":"Ciernikova S, Earl J, Garcia Bermejo ML, Stevurkova V, Carrato A, Smolkova B. Epigenetic landscape in pancreatic ductal adenocarcinoma: on the way to overcoming drug resistance? Int J Mol Sci. 2020;21(11).","DOI":"10.3390\/ijms21114091"},{"issue":"1","key":"2081_CR68","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1756-9966-32-86","volume":"32","author":"J Gao","year":"2013","unstructured":"Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, et al. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res. 2013;32(1):86.","journal-title":"J Exp Clin Cancer Res"},{"key":"2081_CR69","doi-asserted-by":"publisher","first-page":"115384","DOI":"10.1016\/j.ejca.2025.115384","volume":"220","author":"JA Kasmirski","year":"2025","unstructured":"Kasmirski JA, Roy R, Wu C, Wheeler L, Kerrick Akinola K, Chen H, et al. Unraveling the clinical impact of differential DNA methylation in PDAC: a systematic review. Eur J Cancer. 2025;220:115384.","journal-title":"Eur J Cancer"},{"key":"2081_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-8104-5_1","volume-title":"Histone mutations and cancer","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Sun Z, Jia J, Du T, Zhang N, Tang Y, et al. Overview of histone modification. In: Fang D, Han J, editors. Histone mutations and cancer. Singapore: Springer Singapore; 2021. pp. 1\u201316. https:\/\/doi.org\/10.1007\/978-981-15-8104-5_1."},{"key":"2081_CR71","doi-asserted-by":"crossref","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6(10).","DOI":"10.1101\/cshperspect.a026831"},{"issue":"23","key":"2081_CR72","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1007\/s00018-015-2023-y","volume":"72","author":"H Alam","year":"2015","unstructured":"Alam H, Gu B, Lee MG. Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci. 2015;72(23):4577\u201392.","journal-title":"Cell Mol Life Sci"},{"key":"2081_CR73","doi-asserted-by":"crossref","unstructured":"Chen T, Yu H, Wang K, Qin G, Zhao Y, Liang X et al. HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis. J Clin Invest. 2025.","DOI":"10.1172\/JCI195814"},{"issue":"1","key":"2081_CR74","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-024-01907-z","volume":"9","author":"S Casacuberta-Serra","year":"2024","unstructured":"Casacuberta-Serra S, Gonz\u00e1lez-Larreategui \u00cd, Capit\u00e1n-Leo D, Soucek L. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer. Signal Transduct Target Ther. 2024;9(1):205.","journal-title":"Signal Transduct Target Ther"},{"key":"2081_CR75","doi-asserted-by":"publisher","unstructured":"Brown BA, Myers PJ, Adair SJ, Pitarresi JR, Sah-Teli SK, Campbell LA et al. A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreas cancer. 2022. https:\/\/doi.org\/10.1101\/2022.10.19.512869","DOI":"10.1101\/2022.10.19.512869"},{"issue":"5","key":"2081_CR76","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0092-8674(00)82001-2","volume":"87","author":"VV Ogryzko","year":"1996","unstructured":"Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87(5):953\u20139.","journal-title":"Cell"},{"issue":"4","key":"2081_CR77","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrm.2016.143","volume":"18","author":"T Fujisawa","year":"2017","unstructured":"Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017;18(4):246\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2081_CR78","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy. Signal Transduct Target Ther. 2023;8(1):420.","journal-title":"Signal Transduct Target Ther"},{"key":"2081_CR79","doi-asserted-by":"publisher","first-page":"216919","DOI":"10.1016\/j.canlet.2024.216919","volume":"592","author":"AL Miller","year":"2024","unstructured":"Miller AL, Fehling SC, Vance RB, Chen D, Brown EJ, Hossain MI, et al. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine. Cancer Lett. 2024;592:216919. 20240503rd ed.","journal-title":"Cancer Lett"},{"issue":"2","key":"2081_CR80","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0959-437X(02)00287-3","volume":"12","author":"T Kouzarides","year":"2002","unstructured":"Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev. 2002;12(2):198\u2013209.","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"2081_CR81","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jcmgh.2021.09.014","volume":"13","author":"Z Yi","year":"2022","unstructured":"Yi Z, Wei S, Jin L, Jeyarajan S, Yang J, Gu Y, et al. KDM6A regulates cell plasticity and pancreatic cancer progression by noncanonical activin pathway. Cell Mol Gastroenterol Hepatol. 2022;13(2):643\u201367.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"2081_CR82","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-025-61197-z","volume":"16","author":"S Lin","year":"2025","unstructured":"Lin S, Tan S, Peng Y, Tulamaiti A, Du W, Ding K, et al. Histone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling. Nat Commun. 2025;16(1):5947.","journal-title":"Nat Commun"},{"issue":"3","key":"2081_CR83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00432-024-05681-x","volume":"150","author":"K Knipper","year":"2024","unstructured":"Knipper K, Hussein Y, Simon AG, Fretter C, Damanakis AI, Zhao Y, et al. Upregulation of the histone \u03b3-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2024;150(3):137.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2081_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1304639\/full","author":"S Lv","year":"2023","unstructured":"Lv S, Zhang J, Peng X, Liu H, Liu Y, Wei F. Ubiquitin signaling in pancreatic ductal adenocarcinoma. Front Mol Biosci. 2023. https:\/\/doi.org\/10.3389\/fmolb.2023.1304639\/full.","journal-title":"Front Mol Biosci"},{"key":"2081_CR85","doi-asserted-by":"publisher","first-page":"217117","DOI":"10.1016\/j.canlet.2024.217117","volume":"598","author":"X Wang","year":"2024","unstructured":"Wang X, Liu X, Xiao R, Fang Y, Zhou F, Gu M, et al. Histone lactylation dynamics: unlocking the triad of metabolism, epigenetics, and immune regulation in metastatic cascade of pancreatic cancer. Cancer Lett. 2024;598:217117.","journal-title":"Cancer Lett"},{"issue":"4","key":"2081_CR86","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41576-018-0089-8","volume":"20","author":"SL Klemm","year":"2019","unstructured":"Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. Nat Rev Genet. 2019;20(4):207\u201320.","journal-title":"Nat Rev Genet"},{"issue":"2\u20133","key":"2081_CR87","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pbiomolbio.2010.05.001","volume":"102","author":"L Tang","year":"2010","unstructured":"Tang L, Nogales E, Ciferri C. Structure and function of SWI\/SNF chromatin remodeling complexes and mechanistic implications for transcription. Prog Biophys Mol Biol. 2010;102(2\u20133):122\u20138.","journal-title":"Prog Biophys Mol Biol"},{"issue":"2","key":"2081_CR88","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/cas.14768","volume":"112","author":"M Tsuda","year":"2021","unstructured":"Tsuda M, Fukuda A, Kawai M, Araki O, Seno H. The role of the SWI\/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma. Cancer Sci. 2021;112(2):490\u20137. https:\/\/doi.org\/10.1111\/cas.14768.","journal-title":"Cancer Sci"},{"key":"2081_CR89","doi-asserted-by":"publisher","unstructured":"Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, et al. Convergent structural alterations define SWItch\/Sucrose nonfermentable (SWI\/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci. 2012;109(5). https:\/\/doi.org\/10.1073\/pnas.1114817109.","DOI":"10.1073\/pnas.1114817109"},{"issue":"3","key":"2081_CR90","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/cvr\/cvr097","volume":"90","author":"MU Kaikkonen","year":"2011","unstructured":"Kaikkonen MU, Lam MT, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res. 2011;90(3):430\u201340. 20110509th ed.","journal-title":"Cardiovasc Res"},{"key":"2081_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbad004\/7075903","author":"T Liu","year":"2023","unstructured":"Liu T, Chen Z, Chen W, Evans R, Xu J, Reeves ME, et al. Dysregulated MiRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma. Precis Clin Med. 2023. https:\/\/doi.org\/10.1093\/pcmedi\/pbad004\/7075903.","journal-title":"Precis Clin Med"},{"issue":"7","key":"2081_CR92","doi-asserted-by":"publisher","first-page":"101090","DOI":"10.1016\/j.tranon.2021.101090","volume":"14","author":"M Mortoglou","year":"2021","unstructured":"Mortoglou M, Tabin ZK, Arisan ED, Kocher HM, Uysal-Onganer P. Non-coding RNAs in pancreatic ductal adenocarcinoma: new approaches for better diagnosis and therapy. Transl Oncol. 2021;14(7):101090.","journal-title":"Transl Oncol"},{"key":"2081_CR93","doi-asserted-by":"crossref","unstructured":"Takahashi K, Taniue K, Ono Y, Fujiya M, Mizukami Y, Okumura T. Long Non-Coding RNAs in epithelial-mesenchymal transition of pancreatic cancer. Front Mol Biosci. 2021.","DOI":"10.3389\/fmolb.2021.717890"},{"issue":"3","key":"2081_CR94","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1684\/ecn.2024.0495","volume":"35","author":"Z Li","year":"2024","unstructured":"Li Z, Yue C, Hou S, Huang X, Wang Z, Hu W, et al. MALAT1 promotes epithelial-mesenchymal transition of pancreatic cancer cells through the miR-141-5p-TGF-\u00df-TGFBR1\/TGFBR2 axis. Eur Cytokine Netw. 2024;35(3):28\u201337.","journal-title":"Eur Cytokine Netw"},{"key":"2081_CR95","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.canlet.2018.04.035","volume":"432","author":"Z Li","year":"2018","unstructured":"Li Z, Yanfang W, Li J, Jiang P, Peng T, Chen K, et al. Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338\/MACC1\/MET pathway in pancreatic cancer. Cancer Lett. 2018;432:237\u201350.","journal-title":"Cancer Lett"},{"issue":"2","key":"2081_CR96","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1878-0261.13326","volume":"17","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhou J, Zhang H, Ge L, Li J, Wang H. RNA m(6) A methylation in cancer. Mol Oncol. 2023;17(2):195\u2013229.","journal-title":"Mol Oncol"},{"issue":"9","key":"2081_CR97","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.4251\/wjgo.v15.i9.1505","volume":"15","author":"A Bararia","year":"2023","unstructured":"Bararia A, Das A, Mitra S, Banerjee S, Chatterjee A, Sikdar N. Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways. World J Gastrointest Oncol. 2023;15(9):1505\u201319.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"2081_CR98","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.7150\/ijbs.104407","volume":"21","author":"ZH Liu","year":"2025","unstructured":"Liu ZH, Ma P, He Y, Zhang YF, Mou Z, Fang T, et al. The mechanism and latest progress of m6A methylation in the progression of pancreatic cancer. Int J Biol Sci. 2025;21(3):1187\u2013201.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2081_CR99","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12935-025-03922-8","volume":"25","author":"L Liao","year":"2025","unstructured":"Liao L, Xu X, Cao Y, Tang K, Xu Q. Role of m6A RNA methylation regulators in pancreatic cancer: interactions and potential implications. Cancer Cell Int. 2025;25(1):292. https:\/\/doi.org\/10.1186\/s12935-025-03922-8.","journal-title":"Cancer Cell Int"},{"key":"2081_CR100","doi-asserted-by":"publisher","unstructured":"Hara T, Meng S, Arao Y, Saito Y, Inoue K, Rennie S, et al. Recent findings in <\u2009scp>N6 -Methyladenosine modification and significance in pancreatic cancer. Cancer Med. 2025;14(11). https:\/\/doi.org\/10.1002\/cam4.70934.","DOI":"10.1002\/cam4.70934"},{"issue":"1","key":"2081_CR101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13148-021-01046-0","volume":"13","author":"I Lodewijk","year":"2021","unstructured":"Lodewijk I, Nunes SP, Henrique R, Jeronimo C, Duenas M, Paramio JM. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy. Clin Epigenetics. 2021;13(1):63.","journal-title":"Clin Epigenetics"},{"issue":"7577","key":"2081_CR102","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353.","journal-title":"Nature"},{"issue":"7806","key":"2081_CR103","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100\u20135.","journal-title":"Nature"},{"issue":"4","key":"2081_CR104","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4161\/cbt.9.4.10750","volume":"9","author":"A Li","year":"2010","unstructured":"Li A, Omura N, Hong SM, Goggins M. Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors. Cancer Biol Ther. 2010;9(4):321\u20139.","journal-title":"Cancer Biol Ther"},{"key":"2081_CR105","doi-asserted-by":"crossref","unstructured":"Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H et al. DNA methyltransferase Inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1).","DOI":"10.1038\/s41467-017-02630-w"},{"issue":"5","key":"2081_CR106","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.21037\/tcr-20-3295","volume":"10","author":"Y Yang","year":"2021","unstructured":"Yang Y, Su X, Shen K, Zhang C, Dai H, Ma H, et al. PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer. Transl Cancer Res. 2021;10(5):2153\u201368.","journal-title":"Transl Cancer Res"},{"issue":"10","key":"2081_CR107","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00262-024-03786-3","volume":"73","author":"Y Tasiheng","year":"2024","unstructured":"Tasiheng Y, Lin X, Wang X, Zou X, Chen Y, Yan Y, et al. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. Cancer Immunol Immunother. 2024;73(10):208. https:\/\/doi.org\/10.1007\/s00262-024-03786-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2081_CR108","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885\u2013e90010.","journal-title":"Cancer Cell"},{"issue":"2","key":"2081_CR109","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.pan.2019.01.011","volume":"19","author":"G Hu","year":"2019","unstructured":"Hu G, He N, Cai C, Cai F, Fan P, Zheng Z, et al. HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. Pancreatology. 2019;19(2):383\u20139.","journal-title":"Pancreatology"},{"issue":"1","key":"2081_CR110","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.1038\/s41467-023-42178-6","volume":"14","author":"G Liang","year":"2023","unstructured":"Liang G, Oh TG, Hah N, Tiriac H, Shi Y, Truitt ML, et al. Inhibiting stromal class I HDACs curbs pancreatic cancer progression. Nat Commun. 2023;14(1):7791.","journal-title":"Nat Commun"},{"issue":"2","key":"2081_CR111","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1002\/ctm2.654","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang X, Zhu Y, Cao Y, Wang L, Li F, et al. The CTCF\/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression. Clin Transl Med. 2022;12(2):e654.","journal-title":"Clin Transl Med"},{"key":"2081_CR112","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.biocel.2019.01.011","volume":"108","author":"J Zhao","year":"2019","unstructured":"Zhao J, Meng Z, Xie C, Yang C, Liu Z, Wu S, et al. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. 2019;108:84\u201391.","journal-title":"Int J Biochem Cell Biol"},{"issue":"16","key":"2081_CR113","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1158\/1078-0432.CCR-15-2068","volume":"22","author":"Y Huang","year":"2016","unstructured":"Huang Y, Nahar S, Nakagawa A, Fernandez-Barrena MG, Mertz JA, Bryant BM, et al. Regulation of GLI underlies a role for BET bromodomains in pancreatic cancer growth and the tumor microenvironment. Clin Cancer Res. 2016;22(16):4259\u201370.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2081_CR114","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1158\/2159-8290.CD-22-1046","volume":"13","author":"A Bianchi","year":"2023","unstructured":"Bianchi A, De Castro Silva I, Deshpande NU, Singh S, Mehra S, Garrido VT, et al. Cell-Autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer. Cancer Discov. 2023;13(6):1428\u201353.","journal-title":"Cancer Discov"},{"key":"2081_CR115","doi-asserted-by":"crossref","unstructured":"Korbecki J, Barczak K, Gutowska I, Chlubek D, Baranowska-Bosiacka I. CXCL1: Gene, Promoter, regulation of expression, mRNA stability, regulation of activity in the intercellular space. Int J Mol Sci 20220112th ed. 2022;23(2).","DOI":"10.3390\/ijms23020792"},{"key":"2081_CR116","doi-asserted-by":"crossref","unstructured":"Korbecki J, Bosiacki M, Szatkowska I, Kupnicka P, Chlubek D, Baranowska-Bosiacka I. The clinical significance and involvement in molecular cancer processes of chemokine CXCL1 in selected tumors. 25, Int J Mol Sci. 2024.","DOI":"10.3390\/ijms25084365"},{"issue":"2","key":"2081_CR117","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","volume":"42","author":"M DuPage","year":"2015","unstructured":"DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity. 2015;42(2):227\u201338.","journal-title":"Immunity"},{"issue":"11","key":"2081_CR118","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 2018;23(11):3262\u201374.","journal-title":"Cell Rep"},{"issue":"10","key":"2081_CR119","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","volume":"40","author":"X Li","year":"2021","unstructured":"Li X, Su X, Liu R, Pan Y, Fang J, Cao L, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40(10):1836\u201350.","journal-title":"Oncogene"},{"issue":"2","key":"2081_CR120","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/0008-5472.CAN-12-1880","volume":"73","author":"R Shakya","year":"2013","unstructured":"Shakya R, Gonda T, Quante M, Salas M, Kim S, Brooks J, et al. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. Cancer Res. 2013;73(2):885\u201396.","journal-title":"Cancer Res"},{"issue":"5","key":"2081_CR121","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via DsRNA including endogenous retroviruses. Cell. 2015;162(5):974\u201386.","journal-title":"Cell"},{"issue":"5","key":"2081_CR122","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961\u201373.","journal-title":"Cell"},{"issue":"3","key":"2081_CR123","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/2159-8290.CD-20-1202","volume":"11","author":"E Espinet","year":"2021","unstructured":"Espinet E, Gu Z, Imbusch CD, Giese NA, B\u00fcscher M, Safavi M, et al. Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell of origin. Cancer Discov. 2021;11(3):638\u201359.","journal-title":"Cancer Discov"},{"issue":"1","key":"2081_CR124","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41392-021-00769-z","volume":"6","author":"M Zhang","year":"2021","unstructured":"Zhang M, Pan X, Fujiwara K, Jurcak N, Muth S, Zhou J, et al. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Signal Transduct Target Ther. 2021;6(1):366.","journal-title":"Signal Transduct Target Ther"},{"key":"2081_CR125","doi-asserted-by":"crossref","unstructured":"Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife. 2019;8.","DOI":"10.7554\/eLife.50663"},{"issue":"1","key":"2081_CR126","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13046-019-1044-z","volume":"38","author":"P Fan","year":"2019","unstructured":"Fan P, Zhao J, Meng Z, Wu H, Wang B, Wu H, et al. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. J Exp Clin Cancer Res. 2019;38(1):47. https:\/\/doi.org\/10.1186\/s13046-019-1044-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"2081_CR127","doi-asserted-by":"publisher","first-page":"114528","DOI":"10.1016\/j.intimp.2025.114528","volume":"154","author":"Y Jia","year":"2025","unstructured":"Jia Y, Li J, Mei W, Zhang H, Wang Z, Xie X, et al. Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation. Int Immunopharmacol. 2025;154:114528.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2081_CR128","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5306\/wjco.v7.i2.135","volume":"7","author":"I Marchesi","year":"2016","unstructured":"Marchesi I, Bagella L. Targeting enhancer of Zeste homolog 2 as a promising strategy for cancer treatment. World J Clin Oncol. 2016;7(2):135\u201348.","journal-title":"World J Clin Oncol"},{"issue":"5","key":"2081_CR129","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cmet.2024.03.015","volume":"36","author":"J Liu","year":"2024","unstructured":"Liu J, He X, Deng S, Zhao S, Zhang S, Chen Z, et al. QDPR deficiency drives immune suppression in pancreatic cancer. Cell Metab. 2024;36(5):984\u201399. e8.","journal-title":"Cell Metab"},{"issue":"8","key":"2081_CR130","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","volume":"79","author":"S Huang","year":"2019","unstructured":"Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 2019;79(8):2009\u201320.","journal-title":"Cancer Res"},{"issue":"3","key":"2081_CR131","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/2159-8290.CD-20-0519","volume":"11","author":"J Li","year":"2021","unstructured":"Li J, Yuan S, Norgard RJ, Yan F, Sun YH, Kim IK, et al. Epigenetic and transcriptional control of the epidermal growth factor receptor regulates the tumor immune microenvironment in pancreatic cancer. Cancer Discov. 2021;11(3):736\u201353.","journal-title":"Cancer Discov"},{"key":"2081_CR132","doi-asserted-by":"publisher","first-page":"923982","DOI":"10.3389\/fonc.2022.923982","volume":"12","author":"W Duan","year":"2022","unstructured":"Duan W, Wang Z, Qian W, Qi D, Ma Q, Wu E. Editorial: the microenvironment in pancreatic cancer and therapeutic strategies targeting microenvironment. Front Oncol. 2022;12:923982.","journal-title":"Front Oncol"},{"issue":"1","key":"2081_CR133","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/ijc.32072","volume":"145","author":"S Watanabe","year":"2019","unstructured":"Watanabe S, Shimada S, Akiyama Y, Ishikawa Y, Ogura T, Ogawa K, et al. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Int J Cancer. 2019;145(1):192\u2013205.","journal-title":"Int J Cancer"},{"issue":"7","key":"2081_CR134","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022;40(7):768\u2013e7867.","journal-title":"Cancer Cell"},{"key":"2081_CR135","doi-asserted-by":"crossref","unstructured":"Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R et al. SWI\/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 2021;6(18).","DOI":"10.1172\/jci.insight.150453"},{"key":"2081_CR136","doi-asserted-by":"publisher","unstructured":"Pratt HG, Ma L, Dziadowicz SA, Ott S, Whalley T, Szomolay B, et al. Analysis of single nuclear chromatin accessibility reveals unique myeloid populations in human pancreatic ductal adenocarcinoma. Clin Transl Med. 2024;14(3). https:\/\/doi.org\/10.1002\/ctm2.1595.","DOI":"10.1002\/ctm2.1595"},{"issue":"1","key":"2081_CR137","doi-asserted-by":"publisher","first-page":"21226","DOI":"10.1038\/s41598-025-05486-z","volume":"15","author":"J Sun","year":"2025","unstructured":"Sun J, Zhang T, Zhu S. Lactate-related LncRNAs assessment model predicts the prognosis of pancreatic ductal adenocarcinoma. Sci Rep. 2025;15(1):21226.","journal-title":"Sci Rep"},{"issue":"1","key":"2081_CR138","doi-asserted-by":"publisher","first-page":"147","DOI":"10.21037\/gs-21-859","volume":"11","author":"Y Yao","year":"2022","unstructured":"Yao Y, Luo L, Xiang G, Xiong J, Ke N, Tan C, et al. The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma. Gland Surg. 2022;11(1):147\u201365.","journal-title":"Gland Surg"},{"issue":"5","key":"2081_CR139","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s13402-023-00829-2","volume":"46","author":"L Zhu","year":"2023","unstructured":"Zhu L, Li B, Li R, Hu L, Zhang Y, Zhang Z, et al. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Cell Oncol. 2023;46(5):1529\u201341. https:\/\/doi.org\/10.1007\/s13402-023-00829-2.","journal-title":"Cell Oncol"},{"issue":"1","key":"2081_CR140","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41419-025-08156-0","volume":"16","author":"L Wang","year":"2025","unstructured":"Wang L, Chen E, Zhang S, Xiang W, Ye H, Fu Y, et al. Targeting the ac4C \u2018Writer\u2019 NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8\u2009+\u2009T cells and tumor cells. Cell Death Dis. 2025;16(1):809.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2081_CR141","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/SLA.0000000000004147","volume":"275","author":"O Strobel","year":"2022","unstructured":"Strobel O, Lorenz P, Hinz U, Gaida M, K\u00f6nig AK, Hank T, et al. Actual five-year survival after upfront resection for pancreatic ductal adenocarcinoma. Ann Surg. 2022;275(5):962\u201371.","journal-title":"Ann Surg"},{"issue":"1","key":"2081_CR142","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21(1):7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2081_CR143","doi-asserted-by":"crossref","unstructured":"Drizyte-Miller K, Talabi T, Somasundaram A, Cox AD, Der CJ. KRAS: the achilles\u2019 heel of pancreas cancer biology. J Clin Invest. 2025;135(16).","DOI":"10.1172\/JCI191939"},{"issue":"1","key":"2081_CR144","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41419-025-08101-1","volume":"16","author":"L Tian","year":"2025","unstructured":"Tian L, Li H, Cui H, Tang C, Zhao P, Wang X, et al. Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming. Cell Death Dis. 2025;16(1):785.","journal-title":"Cell Death Dis"},{"key":"2081_CR145","doi-asserted-by":"publisher","unstructured":"Liaki V, Barrambana S, Kostopoulou M, Lechuga CG, Zamorano-Dominguez E, Acosta D, et al. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proc Natl Acad Sci. 2025;122(49). https:\/\/doi.org\/10.1073\/pnas.2523039122.","DOI":"10.1073\/pnas.2523039122"},{"key":"2081_CR146","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"S Tan","year":"2020","unstructured":"Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020;124:109821.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2081_CR147","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, Xu D, Liao Mmiao, Sun Y, Bao W, dai, Yao F, et al. Barriers and opportunities in pancreatic cancer immunotherapy. Npj Precis Oncol. 2024;8(1):199.","journal-title":"Npj Precis Oncol"},{"issue":"8056","key":"2081_CR148","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. RNA neoantigen vaccines prime long-lived CD8\u2009+\u2009T cells in pancreatic cancer. Nature. 2025;639(8056):1042\u201351.","journal-title":"Nature"},{"issue":"19","key":"2081_CR149","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; Anti\u2013PD-1 monoclonal Antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286\u201393.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"2081_CR150","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of Anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"8","key":"2081_CR151","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828\u201333.","journal-title":"J Immunother"},{"issue":"1","key":"2081_CR152","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8(1):450.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2081_CR153","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.","journal-title":"J Hematol Oncol"},{"key":"2081_CR154","doi-asserted-by":"crossref","unstructured":"Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: challenges and breakthroughs. Cell Rep Med. 2025;102353.","DOI":"10.1016\/j.xcrm.2025.102353"},{"issue":"11","key":"2081_CR155","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","volume":"37","author":"BA Baldo","year":"2014","unstructured":"Baldo BA. Side effects of cytokines approved for therapy. Drug Saf. 2014;37(11):921\u201343.","journal-title":"Drug Saf"},{"issue":"1","key":"2081_CR156","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Ther. 2024;9(1):68.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2081_CR157","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1007\/s00432-023-04735-w","volume":"149","author":"IP Taylor","year":"2023","unstructured":"Taylor IP, Lopez JA. Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials. J Cancer Res Clin Oncol. 2023;149(10):8117\u201329.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2081_CR158","doi-asserted-by":"publisher","first-page":"115638","DOI":"10.1016\/j.addr.2025.115638","volume":"224","author":"I Maietta","year":"2025","unstructured":"Maietta I, Gonz\u00e1lez-Fern\u00e1ndez \u00c1, Sim\u00f3n-V\u00e1zquez R. Harnessing epigenetic inhibitors: a promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment. Adv Drug Deliv Rev. 2025;224:115638.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2081_CR159","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2217\/epi-2022-0177","volume":"15","author":"S Pandey","year":"2023","unstructured":"Pandey S, Gupta VK, Lavania SP. Role of epigenetics in pancreatic ductal adenocarcinoma. Epigenomics. 2023;15(2):89\u2013110.","journal-title":"Epigenomics"},{"key":"2081_CR160","doi-asserted-by":"crossref","unstructured":"Li Y, Hong YK, Wang X, Pandit H, Zheng Q, Yu Y et al. Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma. Clin Transl Immunol. 2022;11(12).","DOI":"10.1002\/cti2.1430"},{"issue":"1","key":"2081_CR161","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20(1):171.","journal-title":"Mol Cancer"},{"issue":"1","key":"2081_CR162","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000519859","volume":"38","author":"L Versemann","year":"2022","unstructured":"Versemann L, Hessmann E, Ulisse M. Epigenetic therapeutic strategies to target molecular and cellular heterogeneity in pancreatic cancer. Visc Med. 2022;38(1):11\u20139.","journal-title":"Visc Med"},{"key":"2081_CR163","doi-asserted-by":"crossref","unstructured":"Pang L, Zhou F, Liu Y, Ali H, Khan F, Heimberger AB et al. Epigenetic regulation of tumor immunity. J Clin Invest. 2024;134(12).","DOI":"10.1172\/JCI178540"},{"issue":"6","key":"2081_CR164","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/cac2.12546","volume":"44","author":"Y Tang","year":"2024","unstructured":"Tang Y, Cui G, Liu H, Han Y, Cai C, Feng Z, et al. Converting cold to hot: epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer Commun. 2024;44(6):601\u201336.","journal-title":"Cancer Commun"},{"issue":"1","key":"2081_CR165","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-024-01633-x","volume":"16","author":"D Zhu","year":"2024","unstructured":"Zhu D, Zeng S, Su C, Li J, Xuan Y, Lin Y, et al. The interaction between DNA methylation and tumor immune microenvironment: from the laboratory to clinical applications. Clin Epigenetics. 2024;16(1):24. https:\/\/doi.org\/10.1186\/s13148-024-01633-x.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2081_CR166","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13148-021-01100-x","volume":"13","author":"JD Licht","year":"2021","unstructured":"Licht JD, Bennett RL. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clin Epigenetics. 2021;13(1):115. https:\/\/doi.org\/10.1186\/s13148-021-01100-x.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2081_CR167","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13148-025-01856-6","volume":"17","author":"H Zhang","year":"2025","unstructured":"Zhang H, Pang Y, Yi L, Wang X, Wei P, Wang H, et al. Epigenetic regulators combined with tumour immunotherapy: current status and perspectives. Clin Epigenetics. 2025;17(1):51. https:\/\/doi.org\/10.1186\/s13148-025-01856-6.","journal-title":"Clin Epigenetics"},{"key":"2081_CR168","doi-asserted-by":"publisher","unstructured":"Maes K, Mondino A, Lasarte JJ, Agirre X, Vanderkerken K, Prosper F, et al. Epigenetic modifiers: anti-neoplastic drugs with immunomodulating potential. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.652160\/full.","DOI":"10.3389\/fimmu.2021.652160\/full"},{"issue":"9","key":"2081_CR169","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41423-020-0505-9","volume":"17","author":"X Pan","year":"2020","unstructured":"Pan X, Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cell Mol Immunol. 2020;17(9):940\u201353.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2081_CR170","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43556-023-00126-2","volume":"4","author":"Z Xie","year":"2023","unstructured":"Xie Z, Zhou Z, Yang S, Zhang S, Shao B. Epigenetic regulation and therapeutic targets in the tumor microenvironment. Mol Biomed. 2023;4(1):17. https:\/\/doi.org\/10.1186\/s43556-023-00126-2.","journal-title":"Mol Biomed"},{"issue":"1","key":"2081_CR171","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/biom15010071","volume":"15","author":"K Liu","year":"2025","unstructured":"Liu K, Li Y, Shen M, Xu W, Wu S, Yang X, et al. Epigenetic regulation of stromal and immune cells and therapeutic targets in the tumor microenvironment. Biomolecules. 2025;15(1):71.","journal-title":"Biomolecules"},{"issue":"2","key":"2081_CR172","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/biomedicines10020211","volume":"10","author":"Y Liang","year":"2022","unstructured":"Liang Y, Turcan S. Epigenetic drugs and their immune modulating potential in cancers. Biomedicines. 2022;10(2):211.","journal-title":"Biomedicines"},{"issue":"11","key":"2081_CR173","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00535-022-01915-2","volume":"57","author":"K Kawakubo","year":"2022","unstructured":"Kawakubo K, del Castillo CF, Liss AS. Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. J Gastroenterol. 2022;57(11):819\u201326. https:\/\/doi.org\/10.1007\/s00535-022-01915-2.","journal-title":"J Gastroenterol"},{"issue":"12","key":"2081_CR174","doi-asserted-by":"publisher","first-page":"e1430","DOI":"10.1002\/cti2.1430","volume":"11","author":"Y Li","year":"2022","unstructured":"Li Y, Hong YK, Wang X, Pandit H, Zheng Q, Yu Y, et al. Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma. Clin Transl Immunol. 2022;11(12):e1430.","journal-title":"Clin Transl Immunol"},{"issue":"21","key":"2081_CR175","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-20-0285","volume":"80","author":"TA Gonda","year":"2020","unstructured":"Gonda TA, Fang J, Salas M, Do C, Hsu E, Zhukovskaya A, et al. A DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer. Cancer Res. 2020;80(21):4754\u201367.","journal-title":"Cancer Res"},{"issue":"5","key":"2081_CR176","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/S0016-5085(17)30505-X","volume":"152","author":"TA Gonda","year":"2017","unstructured":"Gonda TA, Tycko B, Salas MC, Do C, Fang J, Olive KP. Combination therapy with a hypomethylating drug (Decitabine) plus an immune checkpoint inhibitor (Anti-PD-1H) in the KPC mouse model of pancreatic cancer. Gastroenterology. 2017;152(5):S42\u20133.","journal-title":"Gastroenterology"},{"key":"2081_CR177","doi-asserted-by":"crossref","unstructured":"Orlacchio A, Muzyka S, Li J, Simeone DM, Gonda T. 312 low dose double epigenetic therapy improves immunotherapy response and prolongs survival in pancreatic cancer. Gastroenterology. 2024;166(5).","DOI":"10.1016\/S0016-5085(24)00651-6"},{"issue":"7","key":"2081_CR178","first-page":"3403","volume":"34","author":"K Sugimoto","year":"2014","unstructured":"Sugimoto K, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, et al. Valproic acid enhances the anti-tumor effect of pegylated interferon-\u03b1 towards pancreatic cancer cell lines. Anticancer Res. 2014;34(7):3403\u20139.","journal-title":"Anticancer Res"},{"issue":"10","key":"2081_CR179","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/emmm.201302796","volume":"5","author":"J Li","year":"2013","unstructured":"Li J, Bonifati S, Hristov G, Marttila T, Valmary-Degano S, Stanzel S, et al. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med. 2013;5(10):1537\u201355.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"2081_CR180","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","volume":"6","author":"BJ Christmas","year":"2018","unstructured":"Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res. 2018;6(12):1561\u201377.","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"2081_CR181","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.7150\/jca.44622","volume":"11","author":"YD Kim","year":"2020","unstructured":"Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, et al. HDAC inhibitor, CG-745, enhances the anti-cancer effect of Anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment. J Cancer. 2020;11(14):4059\u201372.","journal-title":"J Cancer"},{"key":"2081_CR182","doi-asserted-by":"crossref","unstructured":"Zhang S, Hu Y, Zhou Z, Lv G, Zhang C, Guo Y et al. ZEB1 promotes chemo-immune resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. J Clin Invest. 2025.","DOI":"10.1172\/JCI195970"},{"issue":"22","key":"2081_CR183","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-21-1141","volume":"27","author":"AI Ali","year":"2021","unstructured":"Ali AI, Wang M, von Scheidt B, Dominguez PM, Harrison AJ, Tantalo DGM, et al. A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer. Clin Cancer Res. 2021;27(22):6222\u201334.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2081_CR184","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/15384047.2018.1507258","volume":"20","author":"L Booth","year":"2019","unstructured":"Booth L, Roberts JL, Poklepovic A, Dent P. Prior exposure of pancreatic tumors to [sorafenib\u2009+\u2009vorinostat] enhances the efficacy of an anti-PD-1 antibody. Cancer Biol Ther. 2019;20(1):109\u201321.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"2081_CR185","doi-asserted-by":"publisher","first-page":"e1581529","DOI":"10.1080\/2162402X.2019.1581529","volume":"8","author":"Y Pan","year":"2019","unstructured":"Pan Y, Fei Q, Xiong P, Yang J, Zhang Z, Lin X, et al. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Oncoimmunology. 2019;8(5):e1581529.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2081_CR186","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13046-024-03268-5","volume":"44","author":"D Oyon","year":"2025","unstructured":"Oyon D, Lopez-Pascual A, Castello-Uribe B, Uriarte I, Orsi G, Llorente S, et al. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2025;44(1):13. https:\/\/doi.org\/10.1186\/s13046-024-03268-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"2081_CR187","doi-asserted-by":"crossref","unstructured":"Principe DR, Xiong R, Li Y, Pham TND, Kamath SD, Dubrovskyi O et al. XP-524 is a dual-BET\/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint Inhibition in pancreatic cancer. Proc Natl Acad Sci U S A. 2022;119(4).","DOI":"10.1073\/pnas.2116764119"},{"issue":"1","key":"2081_CR188","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13148-021-01154-x","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics. 2021;13(1):166.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2081_CR189","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13148-021-01069-7","volume":"13","author":"N Jin","year":"2021","unstructured":"Jin N, George TL, Otterson GA, Verschraegen C, Wen H, Carbone D, et al. Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics. 2021;13(1):83.","journal-title":"Clin Epigenetics"},{"issue":"3","key":"2081_CR190","doi-asserted-by":"publisher","first-page":"958","DOI":"10.7150\/ijbs.103877","volume":"21","author":"R Wang","year":"2025","unstructured":"Wang R, Dong X, Zhang X, Liao J, Cui W, Li W. Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy. Int J Biol Sci. 2025;21(3):958\u201373.","journal-title":"Int J Biol Sci"},{"key":"2081_CR191","doi-asserted-by":"crossref","unstructured":"Rosenberg L, Vabret N. Viral mimicry in cancer therapy. Trends Cancer. 2025.","DOI":"10.1016\/j.trecan.2025.08.010"},{"issue":"1","key":"2081_CR192","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41416-023-02292-0","volume":"129","author":"F Zhong","year":"2023","unstructured":"Zhong F, Lin Y, Zhao L, Yang C, Ye Y, Shen Z. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. Br J Cancer. 2023;129(1):24\u201337.","journal-title":"Br J Cancer"},{"key":"2081_CR193","doi-asserted-by":"publisher","first-page":"115179","DOI":"10.1016\/j.biopha.2023.115179","volume":"165","author":"M Urbanova","year":"2023","unstructured":"Urbanova M, Cihova M, Buocikova V, Slopovsky J, Dubovan P, Pindak D, et al. Nanomedicine and epigenetics: new alliances to increase the odds in pancreatic cancer survival. Biomed Pharmacother. 2023;165:115179.","journal-title":"Biomed Pharmacother"},{"key":"2081_CR194","doi-asserted-by":"publisher","first-page":"1072651","DOI":"10.3389\/fphar.2022.1072651","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang G, Li Y, Lei D, Xiang J, Ouyang L, et al. Recent progress in DNA methyltransferase inhibitors as anticancer agents. Front Pharmacol. 2022;13:1072651.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2081_CR195","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41419-018-0487-z","volume":"9","author":"L Gailhouste","year":"2018","unstructured":"Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Dis. 2018;9(5):468.","journal-title":"Cell Death Dis"},{"issue":"16suppl","key":"2081_CR196","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1200\/JCO.2022.40.16_suppl.4158","volume":"40","author":"RA Safyan","year":"2022","unstructured":"Safyan RA, Manji GA, Lee SM, Silva R, Bates SE, White RA, et al. Phase 2 study of Azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma. J Clin Oncol. 2022;40(16suppl):4158\u20134158. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4158.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2081_CR197","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/ijc.31531","volume":"143","author":"M Chen","year":"2018","unstructured":"Chen M, Nie J, Liu Y, Li X, Zhang Y, Brock MV, et al. Phase Ib\/II study of safety and efficacy of low-dose decitabine\u2010primed chemoimmunotherapy in patients with drug\u2010resistant relapsed\/refractory alimentary tract cancer. Int J Cancer. 2018;143(6):1530\u201340. https:\/\/doi.org\/10.1002\/ijc.31531.","journal-title":"Int J Cancer"},{"key":"2081_CR198","first-page":"1","volume":"2014","author":"H Fan","year":"2014","unstructured":"Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, et al. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I\/II report. J Immunol Res. 2014;2014:1\u201314.","journal-title":"J Immunol Res"},{"issue":"13","key":"2081_CR199","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, et al. Phase I\/Ib clinical trial of Sabatolimab, an Anti\u2013TIM-3 Antibody, alone and in combination with Spartalizumab, an Anti\u2013PD-1 Antibody, in advanced solid tumors. Clin Cancer Res. 2021;27(13):3620\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4suppl","key":"2081_CR200","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1200\/JCO.2022.40.4_suppl.574","volume":"40","author":"S Algaze","year":"2022","unstructured":"Algaze S, Hanna DL, Azad NS, Thomas JS, Iqbal S, Habib D, et al. A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers. J Clin Oncol. 2022;40(4suppl):574\u2013574. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.574.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2081_CR201","doi-asserted-by":"publisher","first-page":"e004495","DOI":"10.1136\/jitc-2022-004495","volume":"10","author":"D Papadatos-Pastos","year":"2022","unstructured":"Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J Immunother Cancer. 2022;10(6):e004495. https:\/\/doi.org\/10.1136\/jitc-2022-004495.","journal-title":"J Immunother Cancer"},{"issue":"16Supplement","key":"2081_CR202","doi-asserted-by":"publisher","first-page":"CT129","DOI":"10.1158\/1538-7445.AM2020-CT129","volume":"80","author":"D Papadatos-Pastos","year":"2020","unstructured":"Papadatos-Pastos D, Pal A, Akay M, Ameratunga M, Mithra S, Ang JE, et al. Abstract CT129: hyper: a phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors. Cancer Res. 2020;80(16Supplement):CT129\u2013129.","journal-title":"Cancer Res"},{"key":"2081_CR203","doi-asserted-by":"publisher","first-page":"S931","DOI":"10.1016\/j.annonc.2024.08.1588","volume":"35","author":"JT Siveke","year":"2024","unstructured":"Siveke JT, Sinn M, Dorman K, Siegler GM, Seufferlein T, Trojan J, et al. 1525P Nab-paclitaxel\/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and Lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: results from the SEPION\/AIO-PAK-0118 phase I\/II s. Ann Oncol. 2024;35:S931.","journal-title":"Ann Oncol"},{"issue":"3","key":"2081_CR204","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-014-2384-1","volume":"73","author":"JJ Wheler","year":"2014","unstructured":"Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014;73(3):495\u2013501. https:\/\/doi.org\/10.1007\/s00280-014-2384-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2081_CR205","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/oncolo\/oyad158","volume":"28","author":"BE Nelson","year":"2023","unstructured":"Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, et al. A phase I trial of bevacizumab and Temsirolimus in combination with valproic acid in advanced solid tumors. Oncologist. 2023;28(12):1100\u2013e1292.","journal-title":"Oncologist"},{"issue":"1","key":"2081_CR206","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","volume":"15","author":"M Baretti","year":"2024","unstructured":"Baretti M, Danilova L, Durham JN, Betts CB, Cope L, Sidiropoulos DN, et al. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Nat Commun. 2024;15(1):9801.","journal-title":"Nat Commun"},{"issue":"16suppl","key":"2081_CR207","doi-asserted-by":"publisher","first-page":"10034","DOI":"10.1200\/JCO.2022.40.16_suppl.10034","volume":"40","author":"CM van Tilburg","year":"2022","unstructured":"van Tilburg CM, Heiss M, \u00d8ra I, Beilken A, Dirksen U, Gottardo NG, et al. Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents: INFORM2 nivent. J Clin Oncol. 2022;40(16suppl):10034\u201310034. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.10034.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2081_CR208","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12885-020-07008-8","volume":"20","author":"CM van Tilburg","year":"2020","unstructured":"van Tilburg CM, Witt R, Heiss M, Pajtler KW, Plass C, Poschke I, et al. INFORM2 nivent: the first trial of the INFORM2 biomarker driven phase I\/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer. 2020;20(1):523.","journal-title":"BMC Cancer"},{"issue":"4","key":"2081_CR209","doi-asserted-by":"publisher","first-page":"102971","DOI":"10.1016\/j.esmoop.2024.102971","volume":"9","author":"E Cartwright","year":"2024","unstructured":"Cartwright E, Slater S, Saffery C, Tran A, Turkes F, Smith G, et al. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE. ESMO Open. 2024;9(4):102971.","journal-title":"ESMO Open"},{"issue":"12","key":"2081_CR210","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41416-023-02267-1","volume":"128","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, et al. Phase I\/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. Br J Cancer. 2023;128(12):2227\u201335.","journal-title":"Br J Cancer"},{"issue":"15suppl","key":"2081_CR211","doi-asserted-by":"publisher","first-page":"TPS5089","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5089","volume":"37","author":"JS De Bono","year":"2019","unstructured":"De Bono JS, Cojocaru E, Plummer ER, Knurowski T, Clegg K, Ashby F, et al. An open label phase I\/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid\/metastatic tumors. J Clin Oncol. 2019;37(15suppl):TPS5089\u20135089. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS5089.","journal-title":"J Clin Oncol"},{"key":"2081_CR212","doi-asserted-by":"crossref","unstructured":"Gounder MM, Martin-Romano P, Italiano A, Siu LL, Cassier PA, Falchook GS et al. Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers. Ann Oncol. 2025.","DOI":"10.1016\/j.annonc.2025.08.3757"},{"issue":"13Supplement","key":"2081_CR213","doi-asserted-by":"publisher","first-page":"CT038","DOI":"10.1158\/1538-7445.AM2017-CT038","volume":"77","author":"D Rasco","year":"2017","unstructured":"Rasco D, Tolcher A, Siu LL, Heinhuis K, Postel-Vinay S, Barbash O, et al. Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin\u2019s lymphoma. Cancer Res. 2017;77(13Supplement):CT038\u2013038.","journal-title":"Cancer Res"},{"key":"2081_CR214","doi-asserted-by":"crossref","unstructured":"Siu LL, Rasco DW, Vinay SP, Romano PM, Menis J, Opdam FL, et al. METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5)inhibitor, in advanced solid tumours. Ann Oncol. 2019;30:v159.","DOI":"10.1093\/annonc\/mdz244"},{"key":"2081_CR215","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00538\/full","author":"ND Ebelt","year":"2020","unstructured":"Ebelt ND, Zuniga E, Johnson BL, Diamond DJ, Manuel ER. 5-Azacytidine potentiates anti-tumor immunity in a model of pancreatic ductal adenocarcinoma. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00538\/full.","journal-title":"Front Immunol"},{"issue":"12","key":"2081_CR216","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5483\/BMBRep.2022.55.12.174","volume":"55","author":"SH Lee","year":"2022","unstructured":"Lee SH, Li Y, Kim H, Eum S, Park K, Lee CH. The role of EZH1 and EZH2 in development and cancer. BMB Rep. 2022;55(12):595\u2013601. https:\/\/doi.org\/10.5483\/BMBRep.2022.55.12.174.","journal-title":"BMB Rep"},{"key":"2081_CR217","doi-asserted-by":"crossref","unstructured":"Hackanson B, Daskalakis M. Decitabine Recent Results Cancer Res. 2014;201:269\u201397.","DOI":"10.1007\/978-3-642-54490-3_18"},{"issue":"1","key":"2081_CR218","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/epi.09.44","volume":"2","author":"LA Cowan","year":"2010","unstructured":"Cowan LA, Talwar S, Yang AS. Will Dna methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine. Solid Tumors Epigenomics. 2010;2(1):71\u201386. https:\/\/doi.org\/10.2217\/epi.09.44.","journal-title":"Solid Tumors Epigenomics"},{"key":"2081_CR219","doi-asserted-by":"publisher","unstructured":"Daskalakis M, Blagitko-Dorfs N, Hackanson B, Decitabine. Recent Results Cancer Res. 2010;184:131\u201357. https:\/\/doi.org\/10.1007\/978-3-642-01222-8_10","DOI":"10.1007\/978-3-642-01222-8_10"},{"key":"2081_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01443\/full","author":"C Fazio","year":"2018","unstructured":"Fazio C, Covre A, Cutaia O, Lofiego MF, Tunici P, Chiarucci C, et al. Immunomodulatory properties of DNA hypomethylating agents: selecting the optimal epigenetic partner for cancer immunotherapy. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.01443\/full.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2081_CR221","first-page":"993","volume":"39","author":"Y Ou","year":"2018","unstructured":"Ou Y, Zhang Q, Tang Y, Lu Z, Lu X, Zhou X, et al. DNA methylation enzyme inhibitor RG108 suppresses the radioresistance of esophageal cancer. Oncol Rep. 2018;39(3):993\u20131002.","journal-title":"Oncol Rep"},{"issue":"5","key":"2081_CR222","first-page":"5799","volume":"16","author":"N Sun","year":"2018","unstructured":"Sun N, Zhang J, Zhang C, Zhao B, Jiao A. DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells. Oncol Lett. 2018;16(5):5799\u2013806.","journal-title":"Oncol Lett"},{"key":"2081_CR223","doi-asserted-by":"publisher","first-page":"107328","DOI":"10.1016\/j.phrs.2024.107328","volume":"207","author":"T Chen","year":"2024","unstructured":"Chen T, Mahdadi S, Vidal M, Desbene-Finck S. Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy. Pharmacol Res. 2024;207:107328.","journal-title":"Pharmacol Res"},{"key":"2081_CR224","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1521550\/full","author":"Y Xu","year":"2025","unstructured":"Xu Y, Zhang H, Nie D. Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1521550\/full.","journal-title":"Front Immunol"},{"issue":"2","key":"2081_CR225","first-page":"166","volume":"3","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3(2):166\u201379.","journal-title":"Am J Transl Res"},{"issue":"1","key":"2081_CR226","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ctrv.2013.05.009","volume":"40","author":"P Bojang","year":"2014","unstructured":"Bojang P, Ramos KS. The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev. 2014;40(1):153\u201369.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2081_CR227","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/j.1476-5381.2010.01188.x","volume":"162","author":"C Tiffon","year":"2011","unstructured":"Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, et al. The histone deacetylase inhibitors Vorinostat and Romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol. 2011;162(7):1590\u2013602.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2081_CR228","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/15384047.2018.1507258","volume":"20","author":"L Booth","year":"2019","unstructured":"Booth L, Roberts JL, Poklepovic A, Dent P. Prior exposure of pancreatic tumors to [sorafenib\u2009+\u2009vorinostat] enhances the efficacy of an anti-PD-1 antibody. Cancer Biol Ther. 2019;20(1):109\u201321. https:\/\/doi.org\/10.1080\/15384047.2018.1507258.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2081_CR229","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/med.21730","volume":"41","author":"E Kulikowski","year":"2021","unstructured":"Kulikowski E, Rakai BD, Wong NCW. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases. Med Res Rev. 2021;41(1):223\u201345. https:\/\/doi.org\/10.1002\/med.21730.","journal-title":"Med Res Rev"},{"issue":"3","key":"2081_CR230","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccell.2018.02.003","volume":"33","author":"J Andricovich","year":"2018","unstructured":"Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell. 2018;33(3):512\u2013e5268.","journal-title":"Cancer Cell"},{"issue":"3","key":"2081_CR231","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41389-020-0218-z","volume":"9","author":"S Zhou","year":"2020","unstructured":"Zhou S, Zhang S, Wang L, Huang S, Yuan Y, Yang J, et al. BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2\/NID1 signaling. Oncogenesis. 2020;9(3):33.","journal-title":"Oncogenesis"},{"issue":"7327","key":"2081_CR232","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"10","key":"2081_CR233","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","volume":"21","author":"PK Mazur","year":"2015","unstructured":"Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, S\u00e1nchez-Rivera FJ, et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015;21(10):1163\u201371.","journal-title":"Nat Med"},{"issue":"7","key":"2081_CR234","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/onc.2015.126","volume":"35","author":"PL Garcia","year":"2016","unstructured":"Garcia PL, Miller AL, Kreitzburg KM, Council LN, Gamblin TL, Christein JD, et al. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene. 2016;35(7):833\u201345.","journal-title":"Oncogene"},{"key":"2081_CR235","doi-asserted-by":"crossref","unstructured":"Kumar K, DeCant BT, Grippo PJ, Hwang RF, Bentrem DJ, Ebine K et al. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight. 2017.","DOI":"10.1172\/jci.insight.88032"},{"key":"2081_CR236","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002746","author":"F Sun","year":"2021","unstructured":"Sun F, Zhu Q, Li T, Saeed M, Xu Z, Zhong F, et al. Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic cancer. Adv Sci. 2021. https:\/\/doi.org\/10.1002\/advs.202002746.","journal-title":"Adv Sci"},{"key":"2081_CR237","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2022.09.006","volume":"27","author":"H Shinohara","year":"2022","unstructured":"Shinohara H, Sawado R, Nakagawa M, Hattori A, Yamagata K, Tauchi K, et al. Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors. Mol Ther Oncolytics. 2022;27:14\u201325.","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"2081_CR238","first-page":"158","volume":"13","author":"R Straining","year":"2022","unstructured":"Straining R, Eighmy W. Tazemetostat: EZH2 inhibitor. J Adv Pr Oncol. 2022;13(2):158\u201363. 20220325th ed.","journal-title":"J Adv Pr Oncol"},{"issue":"6","key":"2081_CR239","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. Med Oncol. 2023;40(6):167.","journal-title":"Med Oncol"},{"issue":"1","key":"2081_CR240","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther. 2024;9(1):332.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2081_CR241","doi-asserted-by":"publisher","first-page":"djw283","DOI":"10.1093\/jnci\/djw283","volume":"109","author":"C Lu","year":"2017","unstructured":"Lu C, Paschall AV, Shi H, Savage N, Waller JL, Sabbatini ME, et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017;109(6):djw283. https:\/\/doi.org\/10.1093\/jnci\/djw283.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2081_CR242","doi-asserted-by":"publisher","first-page":"11450","DOI":"10.1038\/srep11450","volume":"5","author":"JJ Kwon","year":"2015","unstructured":"Kwon JJ, Nabinger SC, Vega Z, Sahu SS, Alluri RK, Abdul-Sater Z, et al. Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Sci Rep. 2015;5(1):11450.","journal-title":"Sci Rep"},{"issue":"3","key":"2081_CR243","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10555-023-10127-w","volume":"42","author":"M Vahabi","year":"2023","unstructured":"Vahabi M, Dehni B, Antom\u00e1s I, Giovannetti E, Peters GJ. Targeting MiRNA and using MiRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. Cancer Metastasis Rev. 2023;42(3):725\u201340. https:\/\/doi.org\/10.1007\/s10555-023-10127-w.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"2081_CR244","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12943-022-01558-0","volume":"21","author":"X Li","year":"2022","unstructured":"Li X, Ma S, Deng Y, Yi P, Yu J. Targeting the RNA m6A modification for cancer immunotherapy. Mol Cancer. 2022;21(1):76. https:\/\/doi.org\/10.1186\/s12943-022-01558-0.","journal-title":"Mol Cancer"},{"issue":"1","key":"2081_CR245","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1038\/s41467-021-25803-0","volume":"12","author":"H Song","year":"2021","unstructured":"Song H, Song J, Cheng M, Zheng M, Wang T, Tian S, et al. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021;12(1):5522.","journal-title":"Nat Commun"},{"issue":"1","key":"2081_CR246","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41467-019-09903-6","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang H, Hu X, Huang M, Liu J, Gu Y, Ma L, et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation. Nat Commun. 2019;10(1):1898.","journal-title":"Nat Commun"},{"issue":"1","key":"2081_CR247","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-021-21514-8","volume":"12","author":"H Yin","year":"2021","unstructured":"Yin H, Zhang X, Yang P, Zhang X, Peng Y, Li D, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat Commun. 2021;12(1):1394.","journal-title":"Nat Commun"},{"issue":"6","key":"2081_CR248","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719\u201334.","journal-title":"Cancer Cell"},{"issue":"6","key":"2081_CR249","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"D Rhim Andrew","year":"2014","unstructured":"Rhim Andrew D, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735\u201347.","journal-title":"Cancer Cell"},{"issue":"6","key":"2081_CR250","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1021\/acs.chemrestox.3c00352","volume":"37","author":"AMB Amorim","year":"2024","unstructured":"Amorim AMB, et al. Advancing drug safety in drug development: bridging computational predictions for enhanced toxicity prediction. Chem Res Toxicol. 2024;37(6):827\u201349.","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"2081_CR251","first-page":"361","volume":"169","author":"KB Chiappinelli","year":"2017","unstructured":"Chiappinelli KB, et al. Inhibiting DNA methylation causes an interferon response in cancer via DsRNA. Including Endogenous Retroviruses Cell. 2017;169(2):361.","journal-title":"Including Endogenous Retroviruses Cell"},{"issue":"8","key":"2081_CR252","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy\u2014current perspectives and future directions. Cell. 2023;186(8):1652\u201369.","journal-title":"Cell"},{"issue":"23","key":"2081_CR253","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343. https:\/\/doi.org\/10.18632\/oncotarget.16723.","journal-title":"Oncotarget"},{"key":"2081_CR254","doi-asserted-by":"crossref","unstructured":"Lu Y et al. Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements. J Adv Res. 2025.","DOI":"10.1016\/j.jare.2025.08.057"},{"issue":"1","key":"2081_CR255","doi-asserted-by":"publisher","first-page":"116738","DOI":"10.1016\/j.celrep.2025.116738","volume":"45","author":"A Huber","year":"2025","unstructured":"Huber A, et al. CRISPR screens define unified hallmarks of cancer cell-autonomous immune evasion. Cell Rep. 2025;45(1):116738.","journal-title":"Cell Rep"},{"key":"2081_CR256","doi-asserted-by":"publisher","unstructured":"Zhang X, Du Y, Behrens A, Lan L. Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance. Dev Cell. 2025 Sep 22;60(18):2391-2406. https:\/\/doi.org\/10.1186\/s12964-023-01302-1","DOI":"10.1186\/s12964-023-01302-1"},{"key":"2081_CR257","doi-asserted-by":"publisher","unstructured":"Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Ploumakis A, et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature. 2016 Sep 1;537(7618):63-68. https:\/\/doi.org\/10.1038\/nature19081","DOI":"10.1038\/nature19081"},{"key":"2081_CR258","doi-asserted-by":"publisher","unstructured":"Ren J, Ren B, Liu X, Cui M, Fang Y, Wang X, et al. Crosstalk between metabolic remodeling and epigenetic reprogramming: A new perspective on pancreatic cancer. Cancer Lett. 2024 Apr 10;587:216649. https:\/\/doi.org\/10.1016\/j.canlet.2024.216649","DOI":"10.1016\/j.canlet.2024.216649"},{"key":"2081_CR259","doi-asserted-by":"publisher","unstructured":"Jiang Z, Zhang H, Gao Y, Sun Y. Multi-omics strategies for biomarker discovery and application in personalized oncology. Mol Biomed. 2025 Nov 21;6(1):115. https:\/\/doi.org\/10.1186\/s43556-025-00340-0","DOI":"10.1186\/s43556-025-00340-0"},{"key":"2081_CR260","doi-asserted-by":"publisher","unstructured":"Fu Y, Tao J, Liu T, Liu Y, Qiu J, Su D, et al. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Mol Cancer. 2024 Jul 9;23(1):140. https:\/\/doi.org\/10.1186\/s12943-024-02050-7","DOI":"10.1186\/s12943-024-02050-7"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02081-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02081-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02081-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:04:02Z","timestamp":1774620242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02081-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":260,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2081"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02081-5","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}